Phaseline

Companies › NervGen Pharma

NervGen Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Neurology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NVG-291
Peptide therapeutic designed to promote nervous system repair and functional recovery
–Phase 3Chronic Spinal Cord InjuryJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07799532NVG-291Phase 3Chronic Spinal Cord InjuryNeurologyJul 2027

From the company's SEC filings

Cash of 22m CAD on 2025-12-31; operating cash outflow about 20m CAD a year; runway about 14 months at that burn, to Feb 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Immunic Alpha Cognition Satellos Bioscience Coya Therapeutics PepGen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.